Activity of the growth hormone-releasing hormone antagonist MIA602 and its underlying mechanisms of action in sarcoidosis-like granuloma.
GHRH antagonist
MIA602
granuloma
sarcoidosis
Journal
Clinical & translational immunology
ISSN: 2050-0068
Titre abrégé: Clin Transl Immunology
Pays: Australia
ID NLM: 101638268
Informations de publication
Date de publication:
2021
2021
Historique:
received:
19
01
2021
revised:
09
04
2021
revised:
11
06
2021
accepted:
15
06
2021
entrez:
14
7
2021
pubmed:
15
7
2021
medline:
15
7
2021
Statut:
epublish
Résumé
Growth hormone-releasing hormone (GHRH) is a potent stimulator of growth hormone (GH) secretion from the pituitary gland. Although GHRH is essential for the growth of immune cells, the regulatory effects of its antagonist in granulomatous disease remain unknown. Here, we report expression of GHRH receptor (R) in human tissue with sarcoidosis granuloma and demonstrate the anti-inflammatory effects of MIA602 (a GHRH antagonist) in two MIA602 decreases the levels of IL-2, IL-2R, IL-7, IL-12, IL-17A and TNF-α in an Our findings further suggest that GHRH-R is potentially a clinical target for the treatment of granulomatous disease and that MIA602 may be used as a novel therapeutic agent for sarcoidosis.
Identifiants
pubmed: 34257968
doi: 10.1002/cti2.1310
pii: CTI21310
pmc: PMC8256670
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1310Informations de copyright
© 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Clin Rev Allergy Immunol. 2015 Aug;49(1):6-18
pubmed: 25771769
Nat Rev Rheumatol. 2011 Jul 12;7(8):457-67
pubmed: 21750528
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Sci Transl Med. 2019 Feb 13;11(479):
pubmed: 30760579
Prostate. 2018 Sep;78(13):970-980
pubmed: 29786867
J Exp Med. 1999 Dec 20;190(12):1879-90
pubmed: 10601362
Am J Respir Crit Care Med. 2016 Jun 1;193(11):1281-91
pubmed: 26649486
Sarcoidosis Vasc Diffuse Lung Dis. 2014 Jul 08;31(2):91-107
pubmed: 25078637
Endocrinology. 2019 Jul 1;160(7):1600-1612
pubmed: 31070727
Front Immunol. 2019 Dec 09;10:2888
pubmed: 31921151
Tanaffos. 2016;15(1):44-7
pubmed: 27403178
Chest. 2015 Feb;147(2):438-449
pubmed: 25188873
Mayo Clin Proc Innov Qual Outcomes. 2019 Aug 02;3(3):358-375
pubmed: 31485575
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
J Vis Exp. 2016 Feb 12;(108):53658
pubmed: 26967380
Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):33-43
pubmed: 18084344
J Clin Endocrinol Metab. 1997 Nov;82(11):3590-6
pubmed: 9360512
J Cell Biochem. 2018 Oct 13;:
pubmed: 30315711
Sci Rep. 2019 Dec 18;9(1):19348
pubmed: 31852980
Am J Respir Cell Mol Biol. 2013 Aug;49(2):180-9
pubmed: 23492192
Postgrad Med. 2017 Jan;129(1):149-158
pubmed: 27766929
Am J Pathol. 1999 Jan;154(1):145-52
pubmed: 9916929
J Hematol Oncol. 2018 Jul 31;11(1):97
pubmed: 30064449
Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20470-5
pubmed: 19075233
Sci Rep. 2020 Apr 29;10(1):7277
pubmed: 32350353
Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):14745-14750
pubmed: 27930339
J Cell Mol Med. 2011 May;15(5):1148-55
pubmed: 20518847
Sci Rep. 2020 Jan 20;10(1):732
pubmed: 31959947
Clin Exp Immunol. 2000 Nov;122(2):241-8
pubmed: 11091281
Lung. 2019 Oct;197(5):541-549
pubmed: 31392398
Histochem Cell Biol. 2008 Jun;129(6):705-33
pubmed: 18461349
Growth Horm IGF Res. 1999 Apr;9 Suppl A:37-44
pubmed: 10429879
Expert Rev Clin Pharmacol. 2018 Jul;11(7):677-687
pubmed: 29883224
Front Pharmacol. 2014 Oct 27;5:233
pubmed: 25386143
Front Immunol. 2018 Nov 09;9:2572
pubmed: 30473698
Am J Respir Crit Care Med. 2014 Sep 1;190(5):560-71
pubmed: 25073001
Eur Respir J. 1999 Oct;14(4):735-7
pubmed: 10573213
Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):18303-8
pubmed: 25489106